Navigation Links
Mylan Receives Approval for Generic Version of Precose® Tablets
Date:1/18/2011

PITTSBURGH, Jan. 18, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg, the generic version of Bayer's Precose® Tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

Acarbose Tablets had U.S. sales of approximately $23 million for the 12 months ending Sept. 30, 2010, according to IMS Health. The product is available for immediate shipment.

Currently, Mylan has 169 ANDAs pending FDA approval representing $99.5 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
2. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
3. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
4. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
5. Mylan Announces the Conversion of its Preferred Stock into Common Stock
6. Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
7. Third Circuit Denies Mylan Motion for Interim Injunction
8. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
11. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Absorption Systems, a global leader in nonclinical testing ... announce that its Chief Operating Officer, Sid Bhoopathy ... the 2017 Executive Management Award. The award is sponsored ... for their creative management vision, leadership philosophy, innovative strategy ... is on March 8, 2017 at the Ballroom at ...
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today ... 2016. Net income attributable to DaVita Inc. ... $158 million, or $0.80 per share and $880 million, or ... attributable to DaVita Inc. for the quarter and year ended ... $192 million, or $0.98 per share, and $789 million, or ...
(Date:2/16/2017)... Feb. 16, 2017 The Lockwood Group (Lockwood), a ... Place to Work in Connecticut list ... third year in a row that Lockwood has been in ... earn the number-two spot in 2017. The award recognizes companies ... The winners were determined through a survey conducted by The ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance ... change designed to further positively impact the health and wellness of our community ... considered it our duty to seriously consider releasing our assets beyond our 5% ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... financial planning assistance to families and business owners in and around the Hampton ... drive to help prevent all forms of domestic violence. , There are multiple ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... planning services to families and entrepreneurs in the Birmingham area, is announcing an ... who needs assistance with her medically challenged son, Anius. , Anius is medically ...
Breaking Medicine News(10 mins):